Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 9 of 13 · 376 total
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully petitioned to institute IPR proceedings against DexCom, Inc.'s patent (11510625) regarding transcutaneous analyte measurement systems. The Board found a reasonable likelihood of prevailing on unpatentability based on alleged anticipation by prior art reference Pace for at least Claim 1.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
The PTAB denied Abbott's second IPR petition against DexCom's '625 patent. The Board ruled that the petitioner failed to demonstrate any material difference in grounds compared to a previously instituted review.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom and Abbott Diabetes Care have settled their dispute over a continuous glucose monitoring patent and jointly moved to terminate the inter partes review. The motion cites a confidential settlement agreement and the lack of any Board decision on the merits.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom and Abbott Diabetes Care settled their IPR dispute over U.S. Patent 11,298,056 covering continuous glucose monitoring technology. The parties filed a joint motion to terminate, and the Board granted termination without a final written decision.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom, Inc. filed a Petition challenging claims 1, 13, and 29 of Abbott Diabetes Care Inc.'s patent (US 11298056). The challenger asserts that these claims are obvious under 35 U.S.C. § 103 based on combinations of prior art references like Patel-2009 and Paradigm® REAL-Time. This petition also argues against discretionary denial, asserting the arguments are new and diligent.
Jeisys Medical Inc. et al. v.Serendia, LLC
EndyMed Medical and Serendia settled their inter partes review disputes over U.S. Patent 9,775,774, leading the PTAB to terminate the proceedings and keep the settlement confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
Serendia requests the USPTO Director to vacate the institution of an IPR against its dermatology device patent after the ITC upheld the patent’s validity, arguing the Board abused discretion and that the Fintiv factors favor denial.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB granted a settlement‑based termination for Jeisys Medical in three IPRs while allowing the proceedings to continue for EndyMed. The settlement agreement was ordered to be kept confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
Jeisys Medical and Serendia have filed a joint request in IPR2024-00383 to keep their settlement agreement confidential under 35 U.S.C. § 317(b). The parties seek to have the agreement treated as business confidential information and kept separate from the patent file.
Jeisys Medical Inc. et al. v.Serendia, LLC
During an IPR hearing, Jeisys Medical announced a settlement with SHEnB and Cartessa respondents, seeking to suspend the schedule until November 20.
Jeisys Medical Inc. et al. v.Serendia, LLC
Jeisys Medical and Serendia settled their IPR dispute over U.S. Patent 9,775,774 and jointly moved to terminate the proceeding.
Jeisys Medical Inc. et al. v.Serendia, LLC
EndyMed Medical and Serendia have filed a joint request to keep their settlement agreement confidential under statutory provisions, separating it from the patent record.
Jeisys Medical Inc. et al. v.Serendia, LLC
Jeisys Medical Inc. challenged Serendia, LLC's '774 patent in an IPR petition, asserting that claims are anticipated by Mehta and rendered obvious through combinations involving Na ’848 and Lee. The petition focuses on the unpatentability of medical device claims related to dermatological treatment/microneedling.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
EndyMed Medical Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia reached a settlement that resolved all disputes over U.S. Patent No. 10,869,812. The Board granted a joint motion to terminate the instituted IPRs and treated the settlement agreement as confidential business information.
EndyMed Medical Ltd. et al. v.Serendia, LLC
EndyMed Medical Ltd. petitions to invalidate Serendia's microneedling patent (10869812) based on anticipation and obviousness over prior art references, including Mehta and Na’848. The petition challenges all 20 claims, arguing that the combination of existing technology renders the claimed invention non-novel or obvious.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical seeks Director Review to overturn a PTAB decision that found several claims of its photodynamic‑therapy device patent unpatentable, arguing the Board mis‑constructed key claim terms and ignored ITC findings.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera’s petition to overturn the PTAB’s obviousness finding on its photodynamic‑therapy illumination patent was rejected. The Board affirmed that the agreed‑upon claim construction was applied and that the prior‑art combination renders the claims obvious. The Director’s request for review was denied.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera has filed an IPR petition challenging Sun Pharmaceutical’s U.S. Patent 11,697,028 covering photodynamic therapy illumination devices, asserting obviousness over Lundahl, Larsen, and Bansal references.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
Biofrontera's IPR challenge against Sun Pharmaceutical regarding photodynamic therapy illuminators was instituted by the PTAB. The Board found a reasonable likelihood of prevailing on obviousness grounds over Lundahl and Larsen, focusing on combining prior art elements for flexible device design.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
3Shape A/S et al. v.Medit Corporation et al.
3Shape and Medit settled their inter partes review dispute over patent 9,262,864 B2. The parties jointly moved to terminate the IPRs, and the Board granted the motion, dismissing the petitions and keeping the settlement confidential.
3Shape A/S et al. v.Medit Corporation et al.
3Shape and Medit have settled their dispute over U.S. Patent 9,262,864, filing a joint motion to terminate the pending inter partes review. The Board has not yet issued an institution decision, and the patent owner did not submit a preliminary response.
Shenzhen Root Technology Co., Ltd. et al. v.Chiaro Technology Ltd.
Shenzhen Root Technology has petitioned the PTAB to invalidate claims 1‑46 of Chiaro Technology’s ‘380 breast‑pump patent, arguing obviousness over a combination of six prior‑art references. The petition stresses examiner error and cites strong discretionary factors favoring institution.
3Shape A/S et al. v.Medit Corporation et al.
3Shape A/S filed an IPR petition challenging Medit Corporation’s patent on digital dentistry technology. The petitioner argues that the claimed 3D scanning methods are obvious under 35 U.S.C. §103, based on combining prior art systems.
Shenzhen Root Technology Co., Ltd. et al. v.Chiaro Technology Ltd.
The PTAB instituted the IPR, finding that Petitioner demonstrated a reasonable likelihood of prevailing on at least one challenged claim. The Board declined discretionary denial despite arguments regarding parallel litigation and prior art cumulative nature.
Shenzhen Root Technology Co., Ltd. et al. v.Chiaro Technology Ltd.
The PTAB issued a Final Written Decision determining that all 46 challenged claims of the '380 patent were unpatentable. The petitioner successfully argued obviousness (103) over various prior art references, including Chang, Fang, and Yuen, concerning breast pump systems.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim, primarily on obviousness grounds involving hemostasis valve features.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care has successfully instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent, asserting anticipation and obviousness over three prior‑art references. The Board found a reasonable likelihood of unpatentability on at least one claim and ordered the trial to proceed.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care seeks an IPR on Inari Medical’s 11,697,012 catheter‑hemostasis valve patent, asserting anticipation and obviousness over Schaffer and related references. The petition argues the preamble term “aspiration” is non‑limiting and requests the Board to institute the review.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.